Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis

N. Kennedy, L. Berger, J. Curram, R. Fox, J. Gutmann, G. M. Kisyombe, F. I. Ngowi, A. R.C. Ramsay, A. O.S. Saruni, N. Sam, G. Tillotson, L. O. Uiso, M. Yates, S. H. Gillespie*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

93 Citations (Scopus)

Abstract

The fluoroquinolones are promising new antituberculous agents. A randomized controlled trial of 200 adult patients with sputum smear positive pulmonary tuberculosis was conducted in Tanzania. Patients received either a trial regimen (HRC) consisting of isoniazid (300 mg), rifampin (600 mg), and ciprofloxacin (750 mg) or a control regimen (HRZE) consisting of isoniazid (300 mg), rifampin (600 mg), pyrazinamide (25 mg/kg), and ethambutol (15 mg/kg). The 168 evaluable patients all had negative smears and cultures by month 6, but the time to conversion to negativity was longer for the HRC group than for the HRZE group because of the poor response of patients infected with human immunodeficiency virus (HIV) to the HRC regimen. Relapse was more frequent in the HRC group. The sterilizing activity of ciprofloxacin does not appear to be equal to that of the combination of pyrazinamide and ethambutol, but the difference in outcome was significant only among HIV- infected patients.

Original languageEnglish
Pages (from-to)827-833
Number of pages7
JournalClinical Infectious Diseases
Volume22
Issue number5
DOIs
Publication statusPublished - 1 Jan 1996

Keywords

  • AIDS-Related Opportunistic Infections/drug therapy
  • Adult
  • Anti-Infective Agents/administration & dosage
  • Antitubercular Agents/administration & dosage
  • Ciprofloxacin/administration & dosage
  • Ethambutol/administration & dosage
  • Female
  • HIV-1
  • Humans
  • Isoniazid/administration & dosage
  • Male
  • Middle Aged
  • Pyrazinamide/administration & dosage
  • Rifampin/administration & dosage
  • Time Factors
  • Tuberculosis, Pulmonary/complications

Fingerprint

Dive into the research topics of 'Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis'. Together they form a unique fingerprint.

Cite this